FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) has announced the drug discovery support AI "Cascade Eye ver. 1.3".

　Cascade Eye uses FRONTEO's natural language analysis AI engine "Concept Encoder (trademark: conceptencoder, reading: concept encoder)" to analyze paper information and medical information, and a network of molecules and genes related to the disease to be analyzed. Is an AI system that displays information in the form of a pathway map (route map showing relevance).Not only does it promote the selection of new drug discovery targets and the efficiency of drug repositioning (diversification of existing drugs to other diseases) research, but it is also evaluated for its ability to perform drug discovery analysis that is not affected by researcher bias. Since its release in 2020, it has been introduced by multiple pharmaceutical companies and academia.

　In Cascade Eye ver. 1.3, the time for AI to generate a network has been greatly reduced to only 10 minutes due to the improvement of the algorithm.In addition, enrichment analysis (Fig. 1) showing biological characteristics such as which organs and functions the molecules and genes displayed on the pathway map are involved in has been added, and a part of the pathway map. Added functions such as a function to delete the user and display only the necessary part, search for molecules / genes included in the pathway map (Fig. 2), and filtering by the strength of the connection between molecules / genes (Fig. 2). And the usability has been improved.In addition, the "Drug Filter" function (Fig. 3) makes it possible to easily check the existence of development products that have the effect of working on the molecules and genes of interest and their development phases.

Figure 1: Enrichment analysis showing biological characteristics such as organs and functions involving molecules and genes

Figure 2: Added search function and filtering function based on the strength of connections between molecules and genes

Figure 3: Displays the presence or absence of development products and the development phase that have the effect of working on the molecule / gene of interest.

　FRONTEO will contribute to improving the quality of medical care by promoting DX (digital transformation) and efficiency improvement of drug discovery research through research and development of AI systems.

■ About Cascade Eye
URL:https://lifescience.fronteo.com/aidiscovery/cascade-eye/
"Cascade Eye" uses FRONTEO's natural language analysis AI engine "Concept Encoder" to analyze papers and medical information, and pathway maps (path maps showing relevance) of molecules and genes related to the disease to be analyzed. It is an AI system that displays in the form of).It visualizes the relationships between molecules and genes, and supports a significant improvement in the efficiency of the target search process in drug discovery research. Since AI comprehensively searches a huge amount of information that cannot be read by humans, it is possible to discover new drug discovery targets and diversion of existing drugs to other diseases without being influenced by researcher bias. It enables drug discovery approaches that were difficult with conventional methods, such as identification of unknown biomarkers.

■ About Concept Encoder
URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO means from a huge amount of text data using the in-house developed AI engine "KIBIT" specializing in natural language processing, "Concept Encoder (trademark: conceptencoder, reading: concept encoder)", and "Looca Cross". It is a data analysis company that extracts important information and supports the business of the company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been deployed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, finance, personnel, and sales support. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

* FRONTEO, KIBIT, conceptencoder, and Cascade Eye are registered trademarks of FRONTEO in Japan.